Antigen | P. vivax (%) | Uninfected (%) | AOR (95% CI) | P-value |
|---|
PvMSP1-19 | 96.9 | 74.1 | 10.7 (3.2, 35.4) |
< 0.0001
|
PvTRAg_2 | 84.4 | 25.4 | 15.7 (8.3, 29.7) |
< 0.0001
|
PvTRAg_28 | 69.8 | 21.9 | 8.2 (4.7, 14.3) |
< 0.0001
|
PvMSP8 | 79.2 | 29.4 | 9.3 (5.2, 16.7) |
< 0.0001
|
PvMSP3 | 70.8 | 25.4 | 7.0 (4.1, 12.1) |
< 0.0001
|
PVDBPII-Sal1 | 47.3 | 16.9 | 5.6 (3.2, 9.7) |
< 0.0001
|
PvDBPII-AH | 78.7 | 30.4 | 14.6 (7.6, 28.2) |
< 0.0001
|
PvRAMA | 90.6 | 42.8 | 12.8 (6.1, 27.0) |
< 0.0001
|
RBP2b | 79.2 | 38.8 | 6.2 (3.5, 11.0) |
< 0.0001
|
PvEBPII | 59.4 | 17.9 | 6.9 (4.0, 12.0) |
< 0.0001
|
- Data presented as seropositivity percentage and odds ratio (95% confidence interval); Multivariate logistic regression analysis was performed to determine the effect of malaria infection on the antibody seropositivity in pregnant women with both P. falciparum and P. vivax infections and without plasmodium infection. Analysis was adjusted for gravidity, body mass index at enrolment, and maternal age enrollment. AOR, Adjusted odds ratio; 95% CI, 95% confidence interval; PV, Plasmodium vivax, RAMA, Rhoptry-associated membrane antigen; MSP, merozoite surface protein; PvTRAg, P. vivax tryptophan-rich antigen; PvEBP, P. vivax erythrocyte-binding protein; PvDBP II-sal1, P. vivax Duffy binding protein region II from ‘sal1’ strain; PvDBP II-AH, Duffy binding protein region II from ‘AH’ strain; RBP2b, reticulocyte binding protein 2b. P values that were less than 0.05 were designated in bold
